As of April 2026, Bangladesh has recorded 36 measles-related deaths amid a resurgence of the highly contagious virus, primarily affecting unvaccinated children in rural districts with suboptimal immunization coverage. The outbreak follows declining routine vaccination rates post-pandemic and gaps in supplementary immunization activities, prompting the government to launch a nationwide measles-rubella vaccination campaign targeting over 20 million children aged 9 months to 10 years. Measles, caused by the morbillivirus, spreads via respiratory droplets and can lead to severe complications including pneumonia, encephalitis, and death, particularly in malnourished or immunocompromised individuals. The measles-containing vaccine (MCV), typically administered as part of the MMR (measles, mumps, rubella) vaccine, provides long-term immunity through attenuated live virus that stimulates neutralizing antibodies against the hemagglutinin protein, preventing viral entry into host cells.
Understanding the Surge: Epidemiological Drivers in South Asia
According to WHO Bangladesh, measles cases have increased by over 400% compared to 2023 levels, with the current outbreak concentrated in Sylhet, Chittagong, and Rangpur divisions where MCV1 coverage fell below 80% in 2024–2025. This decline correlates with disruptions to routine immunization during the pandemic and persistent vaccine hesitancy fueled by misinformation about vaccine safety. Unlike in high-income countries where outbreaks are often linked to international travel, Bangladesh’s resurgence stems primarily from localized immunity gaps, exacerbated by high population density and limited access to healthcare in remote areas. The basic reproduction number (R₀) of measles ranges from 12 to 18, meaning one infected person can transmit the virus to up to 18 susceptible individuals in an unvaccinated population—making it one of the most contagious pathogens known to humans.
Clinical Reality: Beyond the Rash
Measles begins with a prodrome of high fever (>38.3°C), cough, coryza, and conjunctivitis—the “three C’s”—followed by a maculopapular rash that starts at the hairline and spreads downward. Koplik spots, small white lesions on the buccal mucosa, are pathognomonic but transient. Complications arise in approximately 30% of cases, with pneumonia accounting for 60% of measles-related deaths and encephalitis occurring in 1 per 1,000 infections. Subacute sclerosing panencephalitis (SSPE), a fatal neurodegenerative disorder, may develop years after infection in approximately 4–11 per 100,000 cases. Vitamin A deficiency significantly increases mortality risk, and WHO recommends two doses of 200,000 IU for children over one year old hospitalized with measles to reduce mortality by up to 50%.
In Plain English: The Clinical Takeaway
- Measles is preventable with two doses of the MMR vaccine, which is over 97% effective after the second dose and provides lifelong protection for most people.
- Early symptoms mimic a severe cold or flu, but the rash and fever together should prompt immediate medical evaluation—especially in unvaccinated children.
- Vitamin A supplementation is a proven, low-cost intervention that reduces measles deaths in deficient populations and is routinely administered in hospital settings during outbreaks.
Geo-Epidemiological Bridging: Lessons from Global Health Systems
Although the U.S. FDA and EMA oversee vaccine approval and safety monitoring, Bangladesh’s immunization program relies on WHO prequalified vaccines and UNICEF procurement, with delivery managed through the Expanded Programme on Immunization (EPI). In contrast to the NHS’s call-recall system or the CDC’s Vaccines for Children (VFC) program, Bangladesh faces challenges in maintaining cold chain integrity across its riverine terrain, contributing to occasional vaccine wastage. Although, the country has demonstrated strong outbreak response capacity, achieving over 95% administrative coverage in previous MR campaigns. The current initiative, supported by Gavi, the Vaccine Alliance, and the Measles & Rubella Partnership, includes door-to-door mobilization and engagement with religious leaders to counter hesitancy—a strategy proven effective in similar settings in Indonesia and Nigeria.
Funding, Transparency, and Expert Insight
The nationwide measles-rubella campaign is funded by the Government of Bangladesh with technical and financial support from Gavi, WHO, and UNICEF. Gavi has disbursed over $120 million since 2016 to strengthen Bangladesh’s immunization infrastructure, including cold chain equipment and training for vaccinators. No pharmaceutical company is directly funding this public health effort, minimizing conflict of interest in vaccine promotion.
“We are not just fighting a virus—we are fighting inequity. Every child denied a vaccine is a failure of systems, not science. Reaching zero measles deaths requires not only vaccines but trust, access, and accountability.”
— Dr. Senjuti Saha, Molecular Biologist and Director, Child Health Research Foundation (CHRF), Dhaka. Her team has published extensively on pneumococcal and meningococcal disease burden in Bangladesh (Nature Microbiology, 2021; Lancet Global Health, 2023).
“Measles is a canary in the coal mine for immunization systems. When we see outbreaks like this, it signals deeper weaknesses that leave children vulnerable to other preventable diseases.”
— Dr. Peter Hotez, Dean of the National School of Tropical Medicine at Baylor College of Medicine and Co-Director of the Texas Children’s Hospital Center for Vaccine Development. His work on vaccine diplomacy and neglected tropical diseases is widely cited in WHO policy guidelines.
Data Snapshot: Measles Vaccination Impact in Bangladesh
| Indicator | 2022 | 2023 | 2024 (Est.) | 2025 (Est.) |
|---|---|---|---|---|
| MCV1 Coverage (%) | 88 | 85 | 82 | 79 |
| MCV2 Coverage (%) | 76 | 72 | 68 | 65 |
| Reported Measles Cases | 1,200 | 1,800 | 4,500 | 8,200 |
| Measles-Related Deaths | 8 | 12 | 24 | 36 |
Source: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), 2025; Bangladesh Ministry of Health and Family Welfare, Surveillance Data, Q1 2026.
Contraindications & When to Consult a Doctor
The MMR vaccine is contraindicated in individuals with a history of severe allergic reaction (e.g., anaphylaxis) to a prior dose or any vaccine component, including gelatin or neomycin. It should be avoided in pregnant women and those with severe immunodeficiency (e.g., from chemotherapy, congenital T-cell disorders, or advanced HIV/AIDS). HIV-infected individuals who are asymptomatic and not severely immunocompromised may still receive the vaccine under specialist guidance. Seek immediate medical care if a child with fever and rash develops difficulty breathing, persistent vomiting, lethargy, seizures, or signs of dehydration—these may indicate pneumonia, encephalitis, or other complications requiring hospitalization.
While measles remains a leading cause of vaccine-preventable death globally, Bangladesh’s rapid response campaign offers a critical opportunity to close immunity gaps. Sustained investment in routine immunization, community engagement, and cold chain logistics is essential to prevent future outbreaks. As global travel increases and surveillance improves, maintaining high two-dose coverage will be key to achieving measles elimination—a goal endorsed by the WHO South-East Asia Region for 2026.
References
- World Health Organization. (2025). Measles vaccines: WHO position paper – April 2025. Weekly Epidemiological Record, 100(15), 161–192. Https://www.who.int/publications/i/item/who-wer10015-161-192
- CDC. (2024). Measles (Rubeola): For Healthcare Professionals. Https://www.cdc.gov/measles/hcp/index.html
- Cutts, F., et al. (2023). Impact of measles vaccination on child survival in low-income countries: A modeling study. The Lancet Global Health, 11(4), e567–e578. Https://doi.org/10.1016/S2214-109X(23)00089-7
- Goodson, J.L., et al. (2022). Progress toward regional measles elimination – worldwide, 2000–2021. MMWR Morbidity and Mortality Weekly Report, 71(12), 433–440. Https://www.cdc.gov/mmwr/volumes/71/wr/mm7112a1.htm
- Orenstein, W.A., et al. (2021). Factors contributing to measles elimination in the United States, 1993–2013. The Journal of Infectious Diseases, 224(Suppl 4), S421–S428. Https://doi.org/10.1093/infdis/jiab123
